Jay L. Patel
No Rating Available
(Learn About Our Rating System)

Jay L. Patel, MD, MBA

Languages spoken: English

  • Dr. Patel is a Professor in the Department of Pathology at the Spencer Fox Eccles School of Medicine at the University of Utah. In addition, Dr. Patel serves as Vice President of Clinical Trials & PharmaDx at ARUP Laboratories. He received his MD from the University of Arizona and completed a residency in anatomic and clinical pathology at the University of Utah. Dr. Patel then served as a hematopathology fellow at Stanford University. He is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty boards in hematology. Dr. Patel’s clinical and research interests are broad and include all aspects of hematopathology. He is keen on application of next-generation sequencing technologies in the diagnosis and prognostication of hematolymphoid malignancies and benign hematologic disorders.

    Specialties

    Board Certification

    American Board of Pathology (Anatomic & Clinical)
    American Board of Pathology (Sub: Hematology)

  • Dr. Patel is a Professor in the Department of Pathology at the Spencer Fox Eccles School of Medicine at the University of Utah. In addition, Dr. Patel serves as Vice President of Clinical Trials & PharmaDx at ARUP Laboratories. He received his MD from the University of Arizona and completed a residency in anatomic and clinical pathology at the University of Utah. Dr. Patel then served as a hematopathology fellow at Stanford University. He is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty boards in hematology. Dr. Patel’s clinical and research interests are broad and include all aspects of hematopathology. He is keen on application of next-generation sequencing technologies in the diagnosis and prognostication of hematolymphoid malignancies and benign hematologic disorders.

    Board Certification and Academic Information

    Academic Departments Pathology -Primary
    Board Certification
    American Board of Pathology (Anatomic & Clinical)
    American Board of Pathology (Sub: Hematology)

    Education history

    Graduate Training Business Management - University of Utah M.B.A.
    Hematopathology - Stanford University Fellow
    Residency Anatomic and Clinical Pathology - University of Utah Resident
    Medicine - University of Arizona M.D.
    Undergraduate Molecular & Cellular Biology - University of Arizona B.S.

    Selected Publications

    Journal Article

    1. Kaur A, Rojek AE, Symes E, Nawas MT, Patel AA, Patel JL, Sojitra P, Aqil B, Sukhanova M, McNerney ME, Wu LP, Akmatbekov A, Segal J, Tjota MY, Gurbuxani S, Cheng JX, Yeon SY, Ravisankar HV, Fitzpatrick C, Lager A, Drazer MW, Saygin C, Wanjari P, Katsonis P, Lichtarge O, Churpek JE, Ghosh SB, Patel AB, Menon MP, Arber DA, Wang P, Venkataraman G (2024). Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J, 14(1), 99. (Read full article)
    2. Krah NM, Miotke L, Li P, Patel JL, Bowen AR, Pomicter AD, Patel AB (2023). JAK2 R683S Mutation Resulting in Dual Diagnoses of Chronic Eosinophilic Leukemia and Myelodysplastic/Myeloproliferative Overlap Syndrome. J Natl Compr Canc Netw, 21(12), 1218-1223. (Read full article)
    3. Patel JL, Erba HP, Savona MR, Grinblatt DL, Clark M, Clive TC, Smart TB, Makinde AY, DeGutis IS, Yu E, Eggington JM, George TI (2022). Genomic Data Heterogeneity across Molecular Diagnostic Laboratories: A Real-World Connect Myeloid Disease Registry Perspective on Variabilities in Genomic Assay Methodology and Reporting. J Mol Diagn, 25(8), 611-618. (Read full article)
    4. Tomlinson B, de Lima M, Cogle CR, Thompson MA, Grinblatt DL, Pollyea DA, Komrokji RS, Roboz GJ, Savona MR, Sekeres MA, Abedi M, Garcia-Manero G, Kurtin SE, Maciejewski JP, Patel JL, Revicki DA, George TI, Flick ED, Kiselev P, Louis CU, DeGutis IS, Nifenecker M, Erba HP, Steensma DP, Scott BL (2023). Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care. Transplant Cell Ther. (Read full article)
    5. Shomali W, Colucci P, George TI, Kiladjian JJ, Langford C, Patel JL, Reiter A, Vannucchi AM, Gotlib J (2023). Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group. Leukemia. (Read full article)
    6. Agarwal AM, McMurty V, Clayton AL, Bolia A, Reading NS, Mani C, Patel JL, Rets A (2023). Clinical Utility of Targeted Next-Generation Sequencing Panel in Routine Diagnosis of Hereditary Hemolytic Anemia: A national reference laboratory experience. Eur J Haematol, 110(6), 688-695. (Read full article)
    7. Suknuntha K, Geyer JT, Patel KP, Weinberg OK, Rogers HJ, Lake JI, Lauridsen L, Patel JL, Kluk MJ, Arber DA, Hsi ED, Bagg A, Bueso-Ramos C, Orazi A (2023). Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation. Leuk Res, 127, 107033. (Read full article)
    8. Sande CM, Wu R, Yang G, Sussman RT, Bigdeli A, Rushton C, Chitturi A, Patel J, Szankasi P, Morrissette JJD, Lim MS, Elenitoba-Johnson KSJ (2022). Rapid and Automated Semiconductor-Based Next-Generation Sequencing for Simultaneous Detection of Somatic DNA and RNA Aberrations in Myeloid Neoplasms. J Mol Diagn. (Read full article)
    9. Li P, Brown S, Williams M, White TA, Xie W, Cui W, Peker D, Lei L, Kunder CA, Wang HY, Murray SS, Vagher J, Kovacsovics T, Patel JL (2022). The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms. Blood, 140, 716-755. (Read full article)
    10. Hu B, Patel JL, Tao R, Cannon RB, Monroe M, Goyal G (2022). Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation. J Natl Compr Canc Netw, 20(6), 1-4. (Read full article)
    11. Li P, White T, Xie W, Cui W, Peker D, Zeng G, Wang HY, Vagher J, Brown S, Williams M, Kovacsovics T, Patel JL (2021). AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome. Leukemia, 36, 664-674. (Read full article)
    12. Osman A, Patel JL (2021). Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis. Clin Chem, 67, 1062-1070. (Read full article)
    13. Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G, Grinblatt DL, Komrokji RS, Kurtin SE, Maciejewski JP, Pollyea DA, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Dawn Flick E, Kiselev P, Louis CU, Nifenecker M, Swern AS, George TI (2020). Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. Int J Lab Hematol, 43(3), 426-432. (Read full article)
    14. Sireci AN, Patel JL, Joseph L, Hiemenz MC, Rosca OC, Caughron SK, Thibault-Sennett SA, Burke TL, Aisner DL (2020). *Denotes equal contribution. Molecular Pathology Economics 101: An Overview of Molecular Diagnostics Coding, Coverage, and Reimbursement: A Report of the Association for Molecular Pathology. J Mol Diagn, 22(8), 975-993. (Read full article)
    15. Mansoor A, Mansoor MO, Patel JL, Zhao S, Natkunam Y, Bieker JJ (2020). KLF1/EKLF expression in acute leukemia is correlated with chromosomal abnormalities. Blood Cells Mol Dis, 83, 102434. (Read full article)
    16. Schumacher JA, Holgard VD, Sial F, Pearson LN, Patel JL, Karner KH (2019). Detection and Quantification of FLT3 Internal Tandem Duplication Mutations Do Not Vary Significantly Between Whole Blood and Blast-Enriched Samples. Am J Clin Pathol, 153(2), 251-257. (Read full article)
    17. Karner K, George TI, Patel JL (2019). Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis. Ann Lab Med, 39(6), 509-514. (Read full article)
    18. Cessna MH, Paulraj P, Hilton B, Sadre-Bazzaz K, Szankasi P, Cluff A, Patel JL, Hoda D, Toydemir RM (2019). Chronic myelomonocytic leukemia with ETV6-ABL1 rearrangement and SMC1A mutation. Cancer Genet, 238, 31-36. (Read full article)
    19. Corean JLE, George TI, Patel JL, Li KD (2019). Bone marrow findings in metastatic melanoma, including role of BRAF immunohistochemistry. Int J Lab Hematol, 41(4), 550-560. (Read full article)
    20. Shen W, Paxton CN, Szankasi P, Longhurst M, Schumacher JA, Frizzell KA, Sorrells SM, Clayton AL, Jattani RP, Patel JL, Toydemir R, Kelley TW, Xu X (2017). Detection of genome-wide copy number variants in myeloid malignancies using next-generation sequencing. J Clin Pathol, 71(4), 372-378. (Read full article)
    21. Sangle NA, Schmidt RL, Patel JL, Medeiros LJ, Agarwal AM, Perkins SL, Salama ME (2014). Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm. Mod Pathol, 27(8), 1137-43. (Read full article)